Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Cancer Immunol Res. 2016 Dec 21;5(1):17–28. doi: 10.1158/2326-6066.CIR-16-0206

Fig. 2.

Fig. 2

High pretreatment serum ANGPT2 concentrations followed by treatment-induced increases were associated with the worst OS and progressive disease. Data sets from patients receiving ipilimumab, ipilimumab plus bevacizumab or PD-1 blockade were combined and analyzed. A, Kaplan-Meier survival curves based on pretreatment ANGPT2 levels (n = 134). B, Kaplan-Meier survival curves by ANGPT2 fold changes (n = 127). C, Proportions of patients with complete remission/partial remission (CR/PR), stable disease (SD) and progressive disease (PD) according to ANGPT2 fold changes (n = 127). D, Kaplan-Meier survival curves based on pretreatment ANGPT2 concentrations and fold changes (n = 127). E, Proportions of patients with CR/PR, SD, and PD by the combination of pretreatment ANGPT2 levels and fold changes (n = 127).